News

IMGENEX India Collaborates with IIT Roorkee on Breakthrough Antibody Discovery Platform 

Bhubaneswar, January 31, 2026

In a significant advancement for India’s biotechnology and healthcare innovation ecosystem, researchers at Indian Institute of Technology Roorkee have developed a next-generation antibody discovery platform with the potential to transform diagnostics and therapeutics across a wide range of diseases.

The platform integrates cutting-edge approaches, including the development of an ultra-large, high-diversity single-domain antibody (nanobody) library, enabling rapid identification of highly stable and high-affinity antibodies. This innovation is expected to accelerate the development of solutions for cancer, infectious diseases, autoimmune disorders, and emerging pathogens while significantly reducing discovery timelines (www.ndtv.com). 

A notable highlight of this research is the use of shark-derived antibodies, specifically Variable New Antigen Receptors (vNARs). These antibodies are exceptionally small (approximately 12–15 kDa), highly stable, and capable of binding to molecular targets that are often inaccessible to conventional antibodies. Their unique properties allow better tissue penetration and functionality under extreme conditions, making them highly promising for next-generation diagnostics and therapeutics (The Times of India).

The research team has successfully constructed a massive library of nearly 300 billion distinct antibody variants derived from shark immune systems, enabling a universal screening platform against diverse disease targets. Initial validation demonstrated strong binding capabilities across multiple targets, including viral proteins, cancer-associated molecules, and toxins (The Times of India).

Importantly, this breakthrough aligns with India’s vision of Atmanirbhar Bharat, strengthening indigenous capabilities in biologics research, reducing dependence on imports, and supporting affordable healthcare solutions for large populations (www.ndtv.com).

As part of efforts to translate this innovation into real-world applications, IIT Roorkee has entered into a strategic collaboration with IMGENEX India Pvt. Ltd. This partnership focuses on technology transfer, co-development, and commercialization of advanced antibody-based diagnostics and therapeutics. The collaboration aims to accelerate the deployment of cutting-edge solutions, enhance bioprocess development capabilities, and strengthen India’s position in the global biotechnology landscape (www.ndtv.com).

This milestone underscores IMGENEX India’s commitment to advancing translational research and delivering innovative, affordable healthcare technologies, reinforcing its role as a key industry partner in shaping the future of diagnostics and therapeutics.